gregory lesinski
Cited by
Cited by
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
TA Mace, R Shakya, JR Pitarresi, B Swanson, CW McQuinn, S Loftus, ...
Gut 67 (2), 320-332, 2018
Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner
TA Mace, Z Ameen, A Collins, S Wojcik, M Mair, GS Young, JR Fuchs, ...
Cancer research 73 (10), 3007-3018, 2013
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
IH Sahin, M Akce, O Alese, W Shaib, GB Lesinski, B El-Rayes, C Wu
British journal of cancer 121 (10), 809-818, 2019
β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study
S Lemeshow, HT Sørensen, G Phillips, EV Yang, S Antonsen, AH Riis, ...
Cancer epidemiology, biomarkers & prevention 20 (10), 2273-2279, 2011
Novel vaccine strategies to T-independent antigens
GB Lesinski, MAJ Westerink
Journal of microbiological methods 47 (2), 135-149, 2001
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice
BL Mundy-Bosse, GB Lesinski, AC Jaime-Ramirez, K Benninger, M Khan, ...
Cancer research 71 (15), 5101-5110, 2011
Enhanced bioavailability of lycopene when consumed as cis‐isomers from tangerine compared to red tomato juice, a randomized, cross‐over clinical trial
JL Cooperstone, RA Ralston, KM Riedl, TC Haufe, RM Schweiggert, ...
Molecular nutrition & food research 59 (4), 658-669, 2015
The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse
GB Lesinski, M Anghelina, J Zimmerer, T Bakalakos, B Badgwell, ...
The Journal of clinical investigation 112 (2), 170-180, 2003
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells
L Lin, S Deangelis, E Foust, J Fuchs, C Li, PK Li, EB Schwartz, ...
Molecular cancer 9, 1-10, 2010
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma
KA Varker, JE Biber, C Kefauver, R Jensen, A Lehman, D Young, H Wu, ...
Annals of surgical oncology 14, 2367-2376, 2007
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy
BL Mundy-Bosse, GS Young, T Bauer, E Binkley, M Bloomston, MA Bill, ...
Cancer Immunology, Immunotherapy 60, 1269-1279, 2011
Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma
AM Noonan, MR Farren, SM Geyer, Y Huang, S Tahiri, D Ahn, S Mikhail, ...
Molecular Therapy 24 (6), 1150-1158, 2016
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity
MA Bill, JR Fuchs, C Li, J Yui, C Bakan, DM Benson, EB Schwartz, ...
Molecular cancer 9, 1-12, 2010
Vaccines against polysaccharide antigens
GB Lesinski, J Westerink
Current Drug Targets-Infectious Disorders 1 (3), 325-334, 2001
Lipocalin-2 promotes pancreatic ductal adenocarcinoma by regulating inflammation in the tumor microenvironment
SB Gomez-Chou, AK Swidnicka-Siergiejko, N Badi, M Chavez-Tomar, ...
Cancer research 77 (10), 2647-2660, 2017
α-Mangostin: anti-inflammatory activity and metabolism by human cells
F Gutierrez-Orozco, C Chitchumroonchokchai, GB Lesinski, ...
Journal of agricultural and food chemistry 61 (16), 3891-3900, 2013
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease
J Markowitz, TR Brooks, MC Duggan, BK Paul, X Pan, L Wei, Z Abrams, ...
Cancer Immunology, Immunotherapy 64, 149-159, 2015
A mathematical model for pancreatic cancer growth and treatments
Y Louzoun, C Xue, GB Lesinski, A Friedman
Journal of theoretical biology 351, 74-82, 2014
The potential of CAR T cell therapy in pancreatic cancer
M Akce, MY Zaidi, EK Waller, BF El-Rayes, GB Lesinski
Frontiers in immunology 9, 2166, 2018
Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia
YC Tseng, SK Kulp, IL Lai, EC Hsu, WA He, DE Frankhouser, PS Yan, ...
Journal of the National Cancer Institute 107 (12), djv274, 2015
The system can't perform the operation now. Try again later.
Articles 1–20